Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi
How this was made
The 30-second read
Why it matters
The most tradable elements are (1) 75% enrollment with year-end completion expectation, (2) KDIGO 2026 guideline language citing nafamostat as an acceptable CRRT anticoagulant, and (3) updated U.S. CRRT procedure market estimate for 2027, plus (4) cash balance and operating loss trend.
Market read
This filing is a clinical progress and positioning update that can move sentiment ahead of the same-day investor call, but it lacks new clinical efficacy readouts.
What to watch
Cash is $17.1M at June 30, 2026 and expenses rose with enrollment, so dilution or additional financing risk could cap upside even if enrollment continues.
Background
The 8-K (Item 2.02) accompanies Talphera’s Q2 2026 financial results and a corporate update on its nafamostat program (Niyad) in the NEPHRO CRRT Phase 3 registrational study.
Ticker impact
Talphera reports Q2 2026 results and says NEPHRO CRRT enrollment is 75%, with KDIGO 2026 citing nafamostat as an acceptable CRRT anticoagulant.
Moderate upside bias into the Aug 12 investor call, with follow-through dependent on enrollment completion and subsequent regulatory/clinical milestones.
The filing adds concrete progress (75% enrollment), a guideline update referencing nafamostat, and cash runway (cash and investments $17.1M). These are meaningful for a clinical-stage biotech, but there is no approval or new efficacy data disclosed here.
Market effects
Supports sentiment for CRRT anticoagulant development and for companies with nafamostat-based platforms, as guideline language can affect perceived adoption pathways.
Primarily US-focused given the stated U.S. CRRT procedure market sizing and Nasdaq compliance mention.
Limited direct global impact, though KDIGO guidance is international and may influence non-US clinical practice over time.
Counterpoint
Guideline inclusion does not guarantee trial success or approval; the article provides progress and positioning, not new Phase 3 efficacy or safety outcomes.
Key entities
- companyTalphera, Inc.
Nasdaq-listed specialty pharmaceutical company developing nafamostat (Niyad) for CRRT anticoagulation.
- product_candidateNafamostat (Niyad)
Lyophilized nafamostat formulation studied under IDE as an anticoagulant for the extracorporeal circuit.
- clinical_trialNEPHRO CRRT study
Prospective, double-blinded Phase 3 registrational trial targeting 70 adult patients; enrollment reported at 75%.
- regulatory_guidelineKDIGO 2026 Clinical Practice Guideline for AKI/AKD
Guideline language cited in the release as referencing nafamostat as an acceptable regional anticoagulant during CRRT.
